Calliditas Therapeutics AB (publ)
CALTNASDAQHealthcare
$40.00
$-0.04(-0.10%)
Market Cap$2.1B
P/E Ratio—
52W High$43.0
52W Low$15.25
Calliditas Therapeutics AB (publ) (CALT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CALT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.21B | $0.80B | $0.23B | $0.00B | $0.18B |
| Cost of Revenue | $0.08B | $0.02B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $1.13B | $0.79B | $0.23B | $0.00B | $0.18B |
| Gross Margin %(computed) | 93.62% | 98.11% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.50B | $0.41B | $0.36B | $0.24B | $0.15B |
| G&A Expenses | $0.33B | $0.26B | $0.21B | $0.10B | $0.06B |
| Total Operating Expenses | $1.51B | $1.21B | $0.75B | $0.38B | $0.21B |
| Operating Income | ($0.38B) | ($0.42B) | ($0.52B) | ($0.38B) | ($0.03B) |
| Operating Margin %(computed) | -31.85% | -52.55% | -228.67% | — | -15.16% |
| Interest Income | $0.03B | $0.05B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.07B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | ($0.46B) | ($0.41B) | ($0.51B) | ($0.44B) | ($0.03B) |
| Income Tax Expense | $0.01B | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Net Income | ($0.47B) | ($0.41B) | ($0.51B) | ($0.44B) | ($0.03B) |
| Net Margin %(computed) | -38.63% | -51.35% | -222.17% | — | -17.63% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-17.38 | $-15.56 | $-20.04 | $-19.46 | $-1.76 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.02B | 0.02B |
| EBITDA | ($0.37B) | ($0.39B) | ($0.47B) | ($0.38B) | ($0.03B) |
| EBITDA Margin %(computed) | -30.48% | -48.43% | -205.73% | — | -16.42% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · SEK · B
Explore more Calliditas Therapeutics AB (publ) data
About Calliditas Therapeutics AB (publ) (CALT) Income Statement
Calliditas Therapeutics AB (publ) (CALT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CALT reported revenue of $1.21B, gross profit of $1.13B (gross margin 93.62%), and net income of ($0.47B) — a net profit margin of -38.63%.
Frequently asked questions
CALT · 4 questionsCalliditas Therapeutics AB (publ) (CALT) reported revenue of $1.21B for 2023, up 50.3% year-over-year.
CALT revenueCALT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08